Search results for " Eph Family"

showing 2 items of 2 documents

Glypican-3 and Hep Par-1 are Useful Biomarkers in the Cytologic Assessment of Ascites.

2018

Till date, the utility of cytologic assessment of ascites for the identification of hepatocellular carcinoma (HCC) cells is still debated and the usefulness of immunocytochemistry for glypican-3 (GPC3) and Hep Par-1 in this setting has not been reported. Liquid-based cytology of ascitic fluid of 28 cirrhotic patients was performed and the spots obtained were stained with hematoxylin and eosin, papanicolau, and with GPC3 and Hep Par-1 antibodies. GPC3 and Hep Par-1 antibodies stained positively the atypical cells in the ascites of 2 patients with HCC showing an exophytic growth pattern. The specimens of the patients with nonexophytic HCC, other non-HCC cancers, or cirrhosis stained negativel…

0301 basic medicinePathologymedicine.medical_specialtyHistologyCirrhosisCarcinoma HepatocellularH&E stainneoplastic asciteGlypican 3EpitheliumPathology and Forensic Medicineperitoneal effusionDiagnosis Differential03 medical and health sciencesimmunocytochemistry0302 clinical medicineGlypicansCytologyAscitesCarcinomaMedicineHumansProspective StudiesHCCneoplasmsReceptors Eph Familybusiness.industryLiver NeoplasmsAsciteshepatocellular carcinomamedicine.diseaseFibrosisImmunohistochemistryglypican-3digestive system diseasesMedical Laboratory Technology030104 developmental biologyLiver030220 oncology & carcinogenesisHepatocellular carcinomaImmunohistochemistrymedicine.symptomHep Par-1businessApplied immunohistochemistrymolecular morphology : AIMM
researchProduct

Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Epheephrin system

2015

The Eph receptor-ephrin system is an emerging target for the development of novel anti-angiogenic therapies. Research programs aimed at developing small-molecule antagonists of the Eph receptors are still in their initial stage as available compounds suffer from pharmacological drawbacks, limiting their application in vitro and in vivo. In the present work, we report the design, synthesis and evaluation of structure-activity relationships of a class of Δ(5)-cholenoyl-amino acid conjugates as Eph-ephrin antagonists. As a major achievement of our exploration, we identified N-(3β-hydroxy-Δ(5)-cholen-24-oyl)-L-tryptophan (UniPR1331) as the first small molecule antagonist of the Eph-ephrin syste…

MaleModels MolecularAnti-angiogenic agentsAngiogenesis InhibitorsEpheephrin antagonistsPharmacologyEphA2MiceStructure-Activity RelationshipIn vivoCell Line TumorOral bioavailabilityProteineprotein interaction inhibitorsDrug DiscoveryAnimalsHumansStructure–activity relationshipEphrinAmino AcidsReceptorReceptors Eph Familychemistry.chemical_classificationPharmacologyDose-Response Relationship DrugMolecular StructureAnti-angiogenic agents; Bile acids; EphA2; Epheephrin antagonists; Oral bioavailability; Proteineprotein interaction inhibitors; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryErythropoietin-producing hepatocellular (Eph) receptorEndothelial CellsBiological activityGeneral MedicineEPH receptor A2biological factorsBile acidsAmino acidchemistryBiochemistryEphrins
researchProduct